# Inducing Remission in Type 1 Diabetes With Alefacept

> **NCT00965458** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 49 (actual)

## Conditions studied

- New-onset Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Alefacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00965458
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2013-03
- **Final completion:** 2014-04
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Manufacturer discontinued production of Amevive®: business decision.
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00965458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00965458, "Inducing Remission in Type 1 Diabetes With Alefacept". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00965458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*